Can Nitric Oxide–Based Therapy Prevent Bronchopulmonary Dysplasia? - 05/09/12

Doi : 10.1016/j.clp.2012.06.011

Thomas M. Raffay, MD ^a, Richard J. Martin, MD ^a,^⁎ , James D. Reynolds, PhD ^b,^c
^a Division of Neonatology, Department of Pediatrics, Rainbow Babies & Children’s Hospital, Case Medical Center/University Hospitals, 11100 Euclid Avenue, Cleveland, OH 44106-6010, USA
^b Institute for Transformative Molecular Medicine, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106-6010, USA
^c Department of Anesthesia and Perioperative Medicine, Case Medical Center/University Hospitals, 11100 Euclid Avenue, Cleveland, OH 44106-6010, USA

Corresponding author. Rainbow Babies and Children’s Hospital, 11100 Euclid Avenue, RBC Suite 3100, Cleveland, OH 44106-6010.

Résumé

A growing understanding of endogenous nitric oxide (NO) biology is helping to explain how and when exogenous NO may confer benefit or harm; this knowledge is also helping to identify new better-targeted NO-based therapies. In this review, results of the bronchopulmonary dysplasia clinical trials that used inhaled NO in the preterm population are placed in context, the biologic basis for novel NO therapeutics is considered, and possible future directions for NO-focused clinical and basic research in developmental lung disease are identified.

Le texte complet de cet article est disponible en PDF.

Keywords : Inhaled nitric oxide (iNO), Bronchopulmonary dysplasia (BPD), Neonate, Prematurity, S-nitrosylation, S-nitrosothiol (SNO), Ethyl nitrite (ENO)